P2Y12 inhibitors in acute coronary syndrome patients with renal dysfunction: an analysis from the RENAMI and BleeMACS projects

De Filippo, O; D'Ascenzo, F; Raposeiras-Roubin, S; Abu-Assi, E; Peyracchia, M; Bocchino, PP; Kinnaird, T; Ariza-Sole, A; Liebetrau, C; Manzano-Fernandez, S; Boccuzzi, G; Henriques, JPS; Templin, C; Wilton, SB; Omede, P; Velicki, L; Xanthopoulou, I; Correia, L; Cerrato, E; Rognoni, A; Fabrizio, U; Nunez-Gil, I; Iannaccone, M; Montabone, A; Taha, S; Fujii, T; Durante, A; Song, XT; Gili, S; Magnani, G; Varbella, F; Kawaji, T; Blanco, PF; Garay, A; Quadri, G; Alexopoulos, D; Queija, BC; Huczek, Z; Paz, RC; Juanatey, JRG; Fernandez, MC; Nie, SP; Pousa, IM; Kawashiri, MA; Gallo, D; Morbiducci, U; Conrotto, F; Montefusco, A; Dominguez-Rodriguez, A; Lopez-Cuenca, A; Cequier, A; Iniguez-Romo, A; Usmiani, T; Rinaldi, M; De Ferrari, GM

De Filippo, O (corresponding author), Univ Turin, Dept Med Sci, Div Cardiol, AOU Citta Salute & Sci, Corso Bramante 88-90, I-8890 Turin, Italy.

EUROPEAN HEART JOURNAL-CARDIOVASCULAR PHARMACOTHERAPY, 2020; 6 (1): 31

Abstract

Aims The aim of the present study was to establish the safety and efficacy profile of prasugrel and ticagrelor in real-life acute coronary syndrome (A......

Full Text Link